Q-omics provides the consensus-scored KRT41P profile across patient tissues and cancer cell-line models. KRT41P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, KRT41P is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, KRT41P RNA expression shows 6,554 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight THCA, BLCA, and PDAC as cancer lineages where KRT41P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT41P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT41P survival associations across molecular data types. KRT41P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT41P RNA expression–survival associations across cancer types. High KRT41P expression shows unfavorable associations in THCA, LIHC and THYM, but favorable associations in KIRC, BRCA and ESCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for KRT41P RNA expression.
This table summarizes KRT41P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRT41P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT41P shows lower tumor expression in KICH and KIRC and higher tumor expression in BLCA, LUSC, COAD and LUAD. The BLCA box plot shows higher KRT41P RNA expression in tumor versus normal tissue (log2 FC = +0.082, t-test p = .013).
This table shows molecular features associated with KRT41P in patient tissues and cancer cell lines. In patient samples, KRT41P shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
